Breaking News Instant updates and real-time market news.

TSLA

Tesla

$281.13

0.38 (0.14%)

, OKTA

Okta

$60.18

0.28 (0.47%)

09:07
09/07/18
09/07
09:07
09/07/18
09:07

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Okta (OKTA), up 15%. Five Below (FIVE), up 13%... Marvell (MRVL), up 8%... Palo Alto Networks (PANW), up 6%... Broadcom (AVGO), up 3%. DOWN AFTER EARNINGS: eGain (EGAN), down 24%... GameStop (GME), down 4%. ALSO LOWER: Tesla (TSLA), down 7% after Chief Accounting Officer, Dave Morton, provided notice that he was resigning, effective immediately. Additionally, CEO Elon Musk appeared on a podcast last night hosted by Joe Rogan, during which the CEO shared what was said to be a cigarette with marijuana and tobacco comedian... Tilly's (TLYS), down 5% after a 5.5M share secondary offering priced at $18.50 per share... nLight (LASR), down 1.5% after a 4.5M share secondary offering priced at $26.50 per share.

TSLA

Tesla

$281.13

0.38 (0.14%)

OKTA

Okta

$60.18

0.28 (0.47%)

FIVE

Five Below

$115.57

0.8 (0.70%)

MRVL

Marvell

$19.47

-1.02 (-4.98%)

PANW

Palo Alto Networks

$220.13

-2.065 (-0.93%)

AVGO

Broadcom

$216.01

-5.34 (-2.41%)

EGAN

eGain

$12.70

-0.35 (-2.68%)

GME

GameStop

$16.25

-0.02 (-0.12%)

TLYS

Tilly's

$19.72

-2.31 (-10.49%)

LASR

nLight

$27.50

-0.63 (-2.24%)

  • 12

    Sep

  • 13

    Sep

  • 13

    Sep

  • 19

    Sep

  • 19

    Sep

  • 20

    Sep

  • 25

    Sep

  • 10

    Oct

  • 16

    Oct

  • 29

    Oct

  • 15

    Nov

  • 07

    Sep

  • 07

    Sep

TSLA Tesla
$281.13

0.38 (0.14%)

09/06/18
UBSW
09/06/18
NO CHANGE
Target $190
UBSW
Sell
Tesla Model 3 pricing may not be sustainable, says UBS
UBS analyst Colin Langan believes the Tesla Model 3 will be profitable in Q3 and Q4 due to strong pricing. However, he expects profits to decline in 2019 as pricing normalizes. The analyst said the teardown shows a technology edge but he expects that to be challenged due to competition and he expects the Model 3 to miss its gross margins, causing the company to need to raise additional capital. Langan reiterated his Sell rating and lowered his price target to $190 from $195 on Tesla shares.
09/04/18
GSCO
09/04/18
INITIATION
Target $210
GSCO
Sell
Goldman reinstates Sell rating on Tesla, sees 30% downside in shares
Goldman Sachs analyst David Tamberrino reinstated coverage of Tesla and kept a Sell rating on the shares with a six month price target of $210, implying 30.4% downside from current levels. The analyst sees the potential for a "better near-term backdrop" with growth in Model 3 production/deliveries driving positive free cash flow in the second half of 2018. However, he believes this will likely not be sustained as "working capital tailwinds abate" and as spending ramps back up after a period of cash conservation. Further, he views the medium-to-longer term industry backdrop as challenging for Tesla's products. "Intensifying" competition combined with the phase out of the U.S. electric vehicle tax credit for Tesla customers could weigh on company gross margins and profitability, Tamberrino tells investors in a research note.
08/30/18
MSCO
08/30/18
NO CHANGE
Target $291
MSCO
Equal Weight
Morgan Stanley says strong Q3 can 'only go so far' in shifting Tesla narrative
Morgan Stanley analyst Adam Jonas noted that he has assumed a $56,000 average transaction price for Model 3s in Q3, but Tesla may be in a position to sell a large number of Model 3s with high variable margins, which could lead to materially higher average prices and drive top and bottom line outperformance. However, a potentially strong Q3 report, while important, could "only go so far" in shifting the overall investment narrative, Jonas tells investors. Many investors he has spoken with, both bulls and bears, are prepared for the potential of strong results through the remainder of 2018, but the critical question is the difference between achieving results and sustaining them, said Jonas, who keeps his Equal Weight rating and $291 price target on Tesla shares.
09/06/18
OPCO
09/06/18
NO CHANGE
Target $385
OPCO
Outperform
Inside EVs update suggests Tesla Model 3 deliveries tracking well, says Oppenheimer
With concerns around an SEC investigation heating up and Elon Musk continuing to make news for non-business-related concerns, Oppenheimer analyst Colin Rusch believes the controversy around Tesla is pressuring shares lower despite what appears to be meaningful progress on execution issues. The analyst notes Inside EVs is estimating 17,800 Model 3 deliveries for the U.S. in August, bringing the quarter-to-date U.S. delivery estimate to 32,050. Rusch thinks higher volumes improve Tesla's chances of achieving its guidance for Model 3 gross margin at 15%, and would expect shares to rally if it achieves that metric. He reiterates an Outperform rating and $385 price target on the stock.
OKTA Okta
$60.18

0.28 (0.47%)

09/07/18
ADAM
09/07/18
NO CHANGE
Target $75
ADAM
Buy
Okta price target raised to $75 from $60 at Canaccord
Canaccord analyst Richard Davis raised his price target on Okta to $75 from $60 following strong Q2 results. The analyst said Okta is emerging as the "go-to" partner to manage operational efficiency, maintain a single system of record, and ensure organizational security. Davis reiterated his Buy rating on Okta shares.
09/07/18
OPCO
09/07/18
NO CHANGE
Target $80
OPCO
Outperform
Okta price target raised to $80 from $60 at Oppenheimer
Oppenheimer analyst Shaul Eyal reiterated an Outperform rating on Okta and raised his price target to $80 from $60 following the company's "robust" Q2 results and lifted FY19 guidance. In a research note to investors, Eyal says that Okta's customer acquisition and up-sell momentum has illustrated the company's strong position and potential within the identity market, but believes Okta is still early into its "sizable" opportunity, particularly with larger organizations as they shift to cloud environments.
09/07/18
NEED
09/07/18
NO CHANGE
Target $75
NEED
Buy
Okta price target raised to $75 from $58 at Needham
Needham analyst Alex Henderson raised his price target on Oka to $75 and kept his Buy rating after its "streak of beat and raise quarters". The analyst notes that the latest Q2 results showed "strong" revenue and billings growth in spite of the tough compares, as the company "balanced" its new logo adds with accelerated up-selling. Henderson also cites the management's "prudent" guidance, which leaves some room for additional "beat and raise" results.
09/07/18
KEYB
09/07/18
NO CHANGE
Target $74
KEYB
Overweight
Okta price target raised to $74 from $65 at KeyBanc
KeyBanc analyst Rob Owens maintained an Overweight rating on Okta and raised his price target to $74 from $65, telling investors in a research note that the company showcased "meaningful" top-line upside and better-than-expected profitability in its Q2 results. With the Okta opportunity continuing to thrive on an improving appreciation of the value in cloud-based identity, Owens says he continues to identify the potential for further upside.
FIVE Five Below
$115.57

0.8 (0.70%)

09/07/18
JPMS
09/07/18
NO CHANGE
Target $150
JPMS
Overweight
Five Below price target raised to $150 from $116 at JPMorgan
JPMorgan analyst Matthew Boss raised his price target for Five Below to $150 saying the company's growth model is "firing on all cylinders" following last night's Q2 beat. The analyst finds it important that Five Below's comps improved as the quarter progressed. He keeps an Overweight rating on the shares.
09/07/18
DBAB
09/07/18
NO CHANGE
Target $136
DBAB
Buy
Five Below price target raised to $136 from $111 at Deutsche Bank
Deutsche Bank analyst Paul Trussell raised his price target for Five Below to $136 saying the company impressed last night with a 2.7% comp. The analyst still has "strong conviction in this unique retail story" and keeps a Buy rating on the shares.
09/07/18
GDHS
09/07/18
UPGRADE
GDHS
Buy
Five Below upgraded to Buy at Gordon Haskett
09/07/18
RBCM
09/07/18
NO CHANGE
Target $128
RBCM
Outperform
Five Below price target raised to $128 from $114 at RBC Capital
RBC Capital analyst Scot Ciccarelli raised his price target on Five Below to $128 after its Q2 results, saying the company's stacked comps "accelerated meaningfully" on broad-based sales growth. The analyst expects the revenue momentum to persist through Q3, adding that while investors are focused on the comps, Five Below's unit economics and near 20% store growth are also "strong". Ciccarelli keeps his Buy rating, saying he remains bullish on the stock in spite of its premium valuation.
MRVL Marvell
$19.47

-1.02 (-4.98%)

09/07/18
FBCO
09/07/18
NO CHANGE
Target $30
FBCO
Outperform
Marvell has better growth prospects in Storage, says Credit Suisse
Credit Suisse analyst John Pitzer reiterated an Outperform rating and $30 price target following the company's Q2 results. In a research note to investors, Pitzer lowered his FY19 EPS view to $1.24 from $1.40 but raised his FY20 EPS view to $1.55 from $1.50 and said he believes Marvell has better growth prospects in Storage than appreciated as DataCenter and Enterprise content gains are accelerating SSD growth and transforming HDD from a declining business to an "at least flat one." He remains positive on Cavium.
09/07/18
JPMS
09/07/18
DOWNGRADE
JPMS
Overweight
Marvell reinstated with an Overweight from Neutral at JPMorgan
Following a period of restriction, JPMorgan analyst Harlan Sur reinstated coverage of Marvell Technology Group with an Overweight rating and $27 price target. This is an upgrade from the analyst's prior rating of Neutral. Following the acquisition of Cavium, Marvell has created a franchise that is a "powerhouse" in Storage, Networking, embedded processing and high-end wireless connectivity, Sur tells investors in a research note. The analyst sees 30% potential upside in the stock from current levels.
09/07/18
CHLM
09/07/18
NO CHANGE
Target $34
CHLM
Buy
Craig-Hallum 'condient' in earnings power Marvell, Cavium can drive
Craig-Hallum analyst Christian Schwab reiterated a Buy rating and $34 price target on Marvell following the company's Q2 results. In a research note to investors, Schwab says the company's first update since the completion of its acquisition of Cavium gave him increased confidence in the earnings power the combined companies can drive.
09/07/18
OPCO
09/07/18
NO CHANGE
Target $30
OPCO
Outperform
Marvell shares warrant multiple in line with peers, says Oppenheimer
Oppenheimer analyst Rick Schafer reiterated an Outperform rating and $30 price target on Marvell (MRVL) following the company's quarterly results, which topped estimates, though its Q3 outlook was "mixed" compared with the Street. In a research note to investors, Schafer says he likes the strategic accretive Cavium (CAVM) deal, as it strengthens Marvell's exposure to high-end datacenter and networking and doubles its total available market. Schafer also says he believes that adding Cavium improves Marvell's growth and margin profile, warranting a multiple at least in line with peers.
PANW Palo Alto Networks
$220.13

-2.065 (-0.93%)

09/07/18
KEYB
09/07/18
NO CHANGE
Target $275
KEYB
Overweight
Palo Alto Networks price target raised to $275 from $245 at KeyBanc
KeyBanc analyst Rob Owens maintained an Overweight rating on Palo Alto Networks and raise his price target to $275 following the company's quarterly results, telling investors in a research note that the company ended FY18 "on a high note," exceeding estimates across the board. Between the firewall refresh cycle and an expanding opportunity in subscription offerings, Owens contends that the company can continue to achieve upside in the coming year.
09/07/18
RBCM
09/07/18
NO CHANGE
Target $250
RBCM
Outperform
Palo Alto Networks price target raised to $250 from $235 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on Palo Alto Networks to $250 after its "strong" Q4 earnings and better than expected Q1 outlook, saying he is also "increasingly optimistic" around the company's focus on cloud and Application Framework. The analyst cites Palo Alto's 29% billings and revenue growth, 26% product growth, and the addition of about 3K customers over the past two quarters. Hedberg also points to the company's international expansion, with a 43% revenue growth in both APAC and EMEA. The analyst remains convinced that Palo Alto can "consolidate security spend in an expanding total addressable market", driving "above-average growth and margin expansion at scale."
09/07/18
MAXM
09/07/18
NO CHANGE
Target $274
MAXM
Buy
Palo Alto Networks price target raised to $274 from $262 at Maxim
Maxim analyst Nehal Chokshi raised his price target on Palo Alto Networks to $274 and kept his Buy rating after its "strong" Q4 results, saying the quarter again showed subscription revenue exceeding the maintenance sequential growth which suggests "increasing effective attach rates". The analyst also cites the commentary from Palo Also CEO Nihesh Arora and its hints of a "much larger" addressable market that he estimates to be as much as "4-times larger than previously considered".
09/07/18
FBCO
09/07/18
NO CHANGE
Target $185
FBCO
Underperform
Palo Alto Networks price target raised to $185 from $175 at Credit Suisse
Credit Suisse analyst Brad Zelnick maintained an Underperform rating on Palo Alto Networks following above-expectation Q4 results but raised his price target to $185 from $175, telling investors in a research note that while he respects the company's leadership and superlative messaging, he believes his secular call will ultimately prevail as firewalls cede relevance in a "cloud-first world."
AVGO Broadcom
$216.01

-5.34 (-2.41%)

09/07/18
MKMP
09/07/18
NO CHANGE
Target $255
MKMP
Buy
Broadcom price target lowered to $255 from $300 at MKM Partners
MKM Partners analyst Ruben Roy lowered his price target on Broadcom to $255 but raised his FY18 EPS view to $20.56 from $19.93 after its Q2 results. The analyst says the price target change is driven by his adjustment of valuation methodology that assumes lower longer-term growth metrics for Broadcom, even though he keeps a Buy rating on the stock with no change to his assumptions for the company's semiconductor business.
09/07/18
BARD
09/07/18
NO CHANGE
Target $300
BARD
Outperform
Broadcom is new top large-cap semiconductor idea, says Baird
Baird analyst Tristan Gerra called Broadcom his new top idea in the large cap semiconductor space. He said the company has emerged as a particularly attractive value stock compared to more cyclical semi names. He noted management sees continued gross margin expansion ahead for existing products. Gerra reiterated his Outperform rating and raised his price target to $300 from $290 on Broadcom shares.
09/07/18
CHLM
09/07/18
NO CHANGE
Target $300
CHLM
Buy
Broadcom price target cut to $300 from $330 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss reiterated a Buy rating on Broadcom (AVGO) following the company's quarterly results, telling investors in a research note that he likes the rationale behind the CA (CA) deal as the lines blur between hardware and software. While Stoss likes the risk-reward with Broadcom trading at ~10x his FY19 numbers, the analyst lowered his price target to $300 from $330 as he waits for the company to further execute on the CA deal.
09/07/18
BERN
09/07/18
NO CHANGE
Target $310
BERN
Outperform
Broadcom offers attractive risk-reward at current levels, says Bernstein
Bernstein analyst Stacy Rasgon reiterated an Outperform rating and $310 price target on Broadcom (AVGO) following the company's "strong" Q3 report and a similarly strong outlook for Q4. In a research note to investors, Rasgon says that while the recent volatility following the CA (CA) deal announcement was "painful," they may be on the mend as "there was a lot to like" on the company's conference call, including explaining the strategic rationale behind the deal. The stock remains "incredibly cheap," she adds, offering attractive risk-reward.
EGAN eGain
$12.70

-0.35 (-2.68%)

07/18/18
NEED
07/18/18
INITIATION
Target $16
NEED
Buy
eGain initiated with a Buy at Needham
Needham initiated eGain with a Buy and $16 price target.
09/07/18
ROTH
09/07/18
NO CHANGE
Target $16
ROTH
Buy
eGain FY19 guidance looks conservative, says Roth Capital
Roth Capital analyst Richard Baldry noted that eGain's initial FY19 guidance was moderately below his forecast, but he also believes that it appears conservative as he sees the company being positioned to at least grow SaaS revenues on par with FY18, and perhaps better. He reiterates a Buy rating and $16 price target on eGain shares.
07/18/18
NEED
07/18/18
INITIATION
Target $16
NEED
Buy
eGain initiated with a Buy at Needham
Needham analyst Ryan MacDonald imitated eGain with a Buy and $16 price target saying it is a leading provider of cloud-based customer engagement software and expects a re-acceleration of revenue growth and margin expansion in FY19 and FY20, which justifies a premium valuation.
06/07/18
ROTH
06/07/18
NO CHANGE
Target $16
ROTH
Buy
eGain price target raised to $26 from $11 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for eGain to $16 from $11 on accelerating recurring growth. The analyst reiterates a Buy rating on the shares.
GME GameStop
$16.25

-0.02 (-0.12%)

09/05/18
JEFF
09/05/18
NO CHANGE
Target $18
JEFF
Buy
Recent specialty retail M&A implies Gamestop price of $22-$32, says Jefferies
Jefferies analyst Stephanie Wissink noted that "multiple trade reports" have indicated that GameStop is working with an adviser on a formal sale process. Multiples paid in specialty retail transactions during 2018 applied to Gamestop's current stock price imply a takeout price between $22-$32 per share, noted Wissink, who thinks that the stock's depressed valuation, and the company's recent cleansing of its real estate portfolio make the business more attractive now than in the past. She maintains a Buy rating on Gamestop shares with a price target of $18.
09/06/18
LOOP
09/06/18
NO CHANGE
Target $14
LOOP
Hold
GameStop Q2 disappointed on declining operating margins, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $14 price target on GameStop after its Q2 results, saying revenues were below his expectations and comps decline of 0.5% was worse than his expected flat print. The analyst also points to an operating margin decline of 90bps , adding that sales of software, digital, tech brands, and pre-owned merchandise all fell. Chukumba states that he was particularly concerned with continued sales weakness in new video game software and pre-owned and value products, and speculation around private equity interest may eventually become "moot".
09/06/18
BARD
09/06/18
NO CHANGE
Target $14
BARD
Outperform
GameStop strong hardware sales offset pre-owned and software decline, says Baird
Baird analyst Colin Sebastian kept his Outperform rating and $14 price target on GameStop (GME) after its "in-line" Q2 results, where "strong new hardware sales and improving Tech Brands segment profitability" offset the declines in the pre-owned and software segments. The analyst adds that the revenue beat was driven by the ongoing demand for Nintendo (NTDOY) Switch and Xbox One consoles, while noting that the comps decline of -0.5% was better than the expected -3.7% decrease.
09/07/18
WEDB
09/07/18
NO CHANGE
Target $19
WEDB
Outperform
GameStop's demise 'not as imminent as many expect,' says Wedbush
Wedbush analyst Michael Pachter reiterated an Outperform rating and $19 price target on GameStop following the company's Q2 results, telling investors in a research note that he expects shares to trade at a compressed EPS multiple until the company can slow the rate of decline in its core video game business. However, Pachter contends that GameStop will benefit from a strong release slate ahead of the holidays, and that while it is likely going to see sales continue to decline for the foreseeable future, its demise is "not as imminent as many expect" as GameStop appears positioned to manage its store footprint to preserve profitability and cash flow. Regarding its strategic alternatives process, Pachter says he believes the company is "too expensive" for many private equity firms, though it is possible that a buyer could grow free cash flow by cutting opex by $100M or so annually.
TLYS Tilly's
$19.72

-2.31 (-10.49%)

08/30/18
WBLR
08/30/18
UPGRADE
WBLR
Outperform
William Blair upgrades Tilly's to Outperform on improved comp momentum
William Blair analyst Sharon Zackfia upgraded Tilly's to Outperform from Market Perform citing improved comp momentum, easing upcoming comparisons against e-commerce issues in the fourth and first quarters, and increased conviction in the company's potential to grow the unit base from 226 sites today. Following the company's Q2 results, the analyst raised her 2019 earnings estimate by 27% to a Street-high $1.14. The stock offers an attractive valuation, "particularly given the scarcity of relatively open-ended growth ideas in retail," Zackfia tells investors in a research note. Tilly's in premarket trading is up over 15%, or $2.80, to $20.80.
09/04/18
PIVT
09/04/18
DOWNGRADE
Target $22
PIVT
Hold
Tilly's downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Mitch Kummetz downgraded Tilly's to Hold while raising his price target for the shares to $22 from $21. The analyst cites valuation for the downgrade, saying the risk/reward no longer looks favorable at current levels. Shares of Tilly's appear fully valued on current estimates, Kummetz tells investors in a research note.
08/30/18
ROTH
08/30/18
NO CHANGE
Target $22
ROTH
Buy
Tilly's price target raised to $22 from $17 at Roth Capital
Roth Capital analyst Dave King raised his price target for Tilly's to $22 from $17 after Q2 results beat estimates on strong comps and lower than expected expenses, while guidance exceeded expectations on strong Back to School performance. The analyst reiterates a Buy rating on the shares, which reflects Tilly's attractive relative valuation, high concentration of proprietary private label products, limited fashion risk, small relative store footprint, continued tailwinds from recent merchandising improvement initiatives, and the potential for rent relief and further capital return.
08/30/18
08/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tilly's (TLYS) upgraded to Outperform from Market Perform at William Blair with analyst Sharon Zackfia citing improved comp momentum, easing upcoming comparisons against e-commerce issues in the fourth and first quarters, and increased conviction in the company's potential to grow the unit base from 226 sites today. 2. Arlo Technologies (ARLO) upgraded to Buy from Neutral at Guggenheim with analyst Robert Cihra saying the recent pullback in shares offers a compelling buying opportunity and has a meaningful runway to keep growing. 3. Altra Industrial Motion (AIMC) upgraded to Buy from Neutral at Sidoti and to Overweight from Sector Weight at KeyBanc. 4. Genesco (GCO) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz saying the stock's risk/reward looks more favorable following the company's "strong" Q2 results and the continuation of favorable back-to-school trends into Q3. 5. HD Supply (HDS) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
LASR nLight
$27.50

-0.63 (-2.24%)

08/28/18
08/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. II-VI (IIVI) initiated with a Buy at Deutsche Bank while Cree (CREE) was initiated with a Hold. 2. Arlo Technologies (ARLO) initiated with an Outperform at Imperial Capital and Cowen, a Buy at Deutsche Bank, a Neutral at BofA/Merrill and Guggenheim, as well as a Market Perform at Raymond James. 3. AnaptysBio (ANAB) initiated with an Overweight at Cantor Fitzgerald. 4. Oshkosh (OSK) initiated with a Neutral at Buckingham. 5. nLight (LASR) initiated with a Sell at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/18
08/28/18
INITIATION
Target $17

Sell
Benchmark says nLight stock price 'unreasonable,' starts with a Sell
As previously reported, Benchmark analyst Mark Miller started nLight with a Sell rating as he believes the shares may be "priced for perfection" and trading at an "'unreasonable" price with the stock having nearly doubled since the company's April IPO. Additionally, Miller thinks many investors may be ignoring several "yellow flags" regarding nLight's business. He set a $17 price target on nLight shares, which closed yesterday at $31.19.
08/28/18
BNCH
08/28/18
INITIATION
Target $17
BNCH
Sell
nLight initiated with a Sell at Benchmark
Benchmark started nLight with a Sell rating and $17 price target.
08/09/18
STFL
08/09/18
NO CHANGE
Target $40
STFL
Buy
nLight outlook 'clearly bucked' downbeat IPG Photonics commentary, says Stifel
Stifel analyst Patrick Ho said nLIGHT's (LASR) Q2 report was better than his "worst case scenario fears" and its "relatively upbeat" outlook for the September quarter and second half "clearly bucked" the downbeat commentary offered previously by IPG Photonics (IPGP). Ho, who thinks there are some market and company-specific dynamics nLIGHT is experiencing that do not necessarily correlate with the market dynamics IPG is seeing, maintains his Buy rating and $40 price target on nLIGHT shares.

TODAY'S FREE FLY STORIES

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.